403 results about "Ribavirin" patented technology

The invention provides the nucleoside phosphate compound and the preparation and application, which comprises the nucleoside 3', 5'-cyclic phosphate and the 5'-phosphodiester compound. Wherein, the 3', 5'-cyclic phosphate and the derivatives work as the novel HCV inhibitor and the structural formula is shown in the drawing (I), wherein, X equals to OH and F; R equals to H, NH4, R' 4N, R' 3NH and metals such as Na, K, Ca and Li or the structural formula in the drawing (II), R' equals to linear chain or substituted alkane or cyclane, aromatic hydrocarbon, or substituted aromatic hydrocarbon or heterocyclic aromatic hydrocarbon; the four R' and three R' in the amine are the same or different. The invention has the advantages that the nucleoside phosphate compound is used for treating the HCV or is combined with the Alpha-interferon, ribavirin or other anti-HCV drugs to treat the infection of the hepatic c virus or HCV.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.

Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Ribavirin derivatives represented by the formula II, pharmaceutical compositions containing them as well as methods of using the ribavirin derivatives represented by the formula II for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula II are disclosed.

The invention discloses an application of a compound to preparation of medicines for treating viral pneumonia, and relates to the technical field of drugs. The technical problem that novel antiviral drugs are deficient in the prior art, can be solved. The compound comprises a purine compound adopting the structure as shown in the formula 1, and / or an anthraquinone derivative adopting the structureas shown in the formula 2. The purine compound adopting the structure as shown in the formula 1, and / or the anthraquinone derivative adopting the structure as shown in the formula 2 both can show predominant effect for resisting viral pneumonia when being separately used or used jointly. Drugs for treating viral pneumonia, are prepared by the compound provided by the invention are more notable inactivity compared with clinical frontline drugs, and are better than drugs of ribavirin, oseltamivir and the like.

The invention belongs to the technical field of poultry product detection and relates to a combined detection method of amantadine, rimantadine, ribavirin and moroxydine residues in eggs. The method comprises the following steps: carrying out low temperature repetitive freeze-thawing on a sample, adding a formic acid-methanol solution, mixing, centrifuging, taking a supernatant for standby, adding water saturated n-hexane, mixing, carrying out ultrasonic treatment, centrifuging to remove n-hexane floccules on the upper layer with an extracting solution left at the lower layer, purifying with a cation exchange solid-phase extraction column, measuring by a liquid chromatography-tandem mass spectrometer provided with an ESI source, and carrying out accurate qualitative and quantitative analysis on residues of the four antiviral drugs in eggs. The method provided by the invention has high specificity, can accurately and simultaneously measure residual quantity of amantadine, rimantadine, ribavirin and moroxydine without pollution, has high sensitivity, and provides technical support for guaranteeing quality safety of eggs.

The present invention relates to anti-HCV dihaloacetamide compounds in synergistic combination with an interferon and / or ribavirin and pharmaceutical compositions thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compositions to inhibit HCV replication and / or proliferation and to treat or prevent HCV infections.

Reduced gastrointestinal side effect medicaments for treating viral infection in a patient suffering therefrom are provided comprising at least 500 mg of antiviral compound in an oral dosage form that can be administered in effective total daily dosages of antiviral compound ranging from 1000 mg to 2000 mg. The reduced gastrointestinal side effect medicaments enhance patient compliance with long term, multi-dose treatment regimens by reducing physiological and psychological side effects that can cause reductions or discontinuations of antiviral therapy. Exemplary antiviral compounds include nucleoside analogues such as ribavirin, levovirin, and viramindine which are effective when combined with interferon to treat acute or chronic viral infections including hepatitis, and particularly hepatitis C. Associated methods for the production and use of the medicaments also are provided.

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.

The invention relates to oral pharmaceutical compositions for the prevention and / or the treatment of viral diseases. This invention also addresses methods of prevention and / or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C virus by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of patients. Said composition comprises at least one modified release form of ribavirin, the bio-absorption time BAT of which is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 h and more preferably between 4 and 12 h. Said composition is a reservoir type form or a matrix type form. Said composition is a gastric retentive system or a multiparticulate form.

The Ribavirin inhalation is a kind of respiratory tract mucous membrane absorbed preparation comprising superfine Ribavirin powder and fine medicinal carrier powder and is administrated with special administrating device. It has high and fast target effect, safe antiviral function, no stimulation to mucous membrane and other advantages. The present invention further expands the clinical application range of Ribavirin.